Y Intercept Hong Kong Ltd decreased its position in GSK plc (NYSE:GSK - Free Report) by 23.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,078 shares of the pharmaceutical company's stock after selling 15,977 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in GSK were worth $2,170,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC increased its holdings in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock worth $1,185,885,000 after buying an additional 2,224,345 shares during the period. Fisher Asset Management LLC increased its stake in GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock worth $759,425,000 after purchasing an additional 870,449 shares during the period. Primecap Management Co. CA boosted its stake in shares of GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company's stock valued at $607,222,000 after purchasing an additional 342,365 shares during the period. Provident Trust Co. grew its holdings in shares of GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company's stock worth $161,623,000 after purchasing an additional 66,765 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC increased its stake in shares of GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company's stock worth $144,803,000 after buying an additional 833,080 shares during the period. Hedge funds and other institutional investors own 15.74% of the company's stock.
Analyst Ratings Changes
Several brokerages have weighed in on GSK. Barclays raised shares of GSK to a "hold" rating in a research report on Tuesday, August 27th. Jefferies Financial Group cut GSK from a "buy" rating to a "hold" rating and cut their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Guggenheim lowered GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Finally, StockNews.com downgraded GSK from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 4th. Seven investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $43.25.
Get Our Latest Stock Report on GSK
Insider Transactions at GSK
In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the stock in a transaction on Friday, September 27th. The stock was acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares of the company's stock, valued at $134,205,528. This represents a 19.97 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.00% of the company's stock.
GSK Stock Down 2.2 %
Shares of NYSE:GSK traded down $0.80 during trading on Tuesday, hitting $35.19. The stock had a trading volume of 5,382,868 shares, compared to its average volume of 4,166,355. The company has a market capitalization of $72.93 billion, a PE ratio of 22.86, a PEG ratio of 1.33 and a beta of 0.64. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The firm's fifty day moving average is $36.56 and its 200 day moving average is $39.50. GSK plc has a 12 month low of $32.83 and a 12 month high of $45.92.
GSK Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.47%. The ex-dividend date is Friday, November 15th. This is a boost from GSK's previous quarterly dividend of $0.38. GSK's payout ratio is 99.35%.
GSK Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
